Proof of Concept (POC) in Patients With Ischaemic Stroke

A phase 2 trial registered on ClinicalTrials.gov. The registry status is terminated. It enrolled 134 participants.

Also called NCT01808261

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 134 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT01808261
Other papers using this trial's data
  • Proof-of-Concept Randomized Trial of the Monoclonal Antibody GSK249320 Versus Placebo in Stroke Patients Stroke, 2017-03 DOI, PubMed 28228578, PMC5325241 In the PMC Open Access subset under CC BY-NC-ND.

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Canada, Germany, United Kingdom (from the registry)
Registry status
  • Terminated (from the registry)

Technical summary

Registry record NCT01808261. Randomized; double masking; primary purpose treatment. Start 2013-05-18 (actual); primary completion 2014-07-28 (actual). Results posted on 2017-10-03.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Proof of Concept (POC) in Patients With Ischaemic Stroke
Condition
Cerebrovascular Accident
Intervention (Drug)
GSK249320 100/mg
Intervention (Drug)
Placebo
Lead sponsor
GlaxoSmithKline (class: industry)

Record details

Record id
cardio:ct-nct01808261
Content hash
b5a9dd74158c20f65497d86e9a52c4c94baa93e7bdfe7d68eaf66f9d58f9571b